OGT and Intelliseq have joined forces to bring you an exciting partnership.
Together, we offer tertiary interpretation and customized reporting solutions for the SureSeq™ NGS portfolio, which is made possible by Intelliseq’s advanced iFlow™ engine.
Intelliseq, a leading genome informatics company and provider of next-generation sequencing (NGS) analysis solutions, brings innovation and expertise to this collaboration.
With the addition of Intelliseq’s iFlow™ engine, we now offer our customers a comprehensive myeloid analysis, from sample to report.
Powered by Sureseq’s leading-class bioinformatics pipeline, GeneSpect Somatic Reporter provides NGS interpretation in accordance with the most recent AMP/ACMG biomarker classifications. Actionable insights, drug/therapy associations, and clinical trials are also provided, providing a comprehensive picture for myeloid researchers.
Figure 1: An AML somatic sample report generated by GenSpect. Details on the report include, variant classification, FDA therapy recommendation and available clinical trial options.
Work with our team of variant science experts to generate custom analyses or report templates. We ensure your reports enable you to obtain the most from your NGS data.
NGS has the potential to provide valuable insights into cancer research, and clinicians need help deciphering this data. The SureSeq platform partnered with the GeneSpect Somatic Reporter simplifies this critical step for its users, ensuring they maximise the benefits of their NGS data to progress our understanding on cancer.
Adrian Smith
Chief Executive Officer, OGT
For more information about how the OGT and Intelliseq partnership can help your lab please complete the contact form and one of our NGS experts will be in touch soon.
Contact us
Visit International site
Visit Canada site
International